Characteristics of the level-of-evidence-1 disease forecast cancer biomarkers uPA and its inhibitor PAI-1

Karin Mengele; Rudolf Napieralski; Viktor Magdolen; Ute Reuning; Apostolos Gkazepis; Fred  Sweep; Nils Brunner; John Foekens; Nadia Harbeck; Manfred Schmitt

doi:10.1586/erm.10.73

Characteristics of the level-of-evidence-1 disease forecast cancer biomarkers uPA and its inhibitor PAI-1

Karin Mengele , Rudolf Napieralski, Viktor Magdolen, Ute Reuning, Apostolos Gkazepis, Fred Sweep, Nils Brunner, John Foekens, Nadia Harbeck, Manfred Schmitt

38 Citations (Scopus)

1 Downloads (Pure)

Abstract

In cancer, the serine protease urokinase-type plasminogen activator, its inhibitor (plasminogen activator inhibitor type-1) and the receptor (CD87), among other proteolytic factors, are involved in tumor cell dissemination and turnover of the extracellular matrix. Unsurprisingly, a battery of very uniform data, amassed since the end of the 1990s, has put these members of the plasminogen activation system into the forefront of prognostic/predictive cancer biomarkers relevant to predict the clinical course of cancer patients and their response to cancer therapy. The present review focuses on the molecular characteristics of the disease forecast biomarkers urokinase-type plasminogen activator and plasminogen activator inhibitor type-1, and techniques to quantitatively assess these cancer biomarkers, in the context of potential clinical application and personalized disease management.

Original language	English
Journal	Expert Review of Molecular Diagnostics
Volume	10
Issue number	7
Pages (from-to)	947-962
Number of pages	16
ISSN	1473-7159
DOIs	https://doi.org/10.1586/erm.10.73
Publication status	Published - Jul 2010

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1586/erm.10.73

Characteristics of the level-of-evidence-1 diseaseFinal published version, 9.79 MB

Cite this

@article{3d80272e2c73439d8bea615b09cae19b,

title = "Characteristics of the level-of-evidence-1 disease forecast cancer biomarkers uPA and its inhibitor PAI-1",

abstract = "In cancer, the serine protease urokinase-type plasminogen activator, its inhibitor (plasminogen activator inhibitor type-1) and the receptor (CD87), among other proteolytic factors, are involved in tumor cell dissemination and turnover of the extracellular matrix. Unsurprisingly, a battery of very uniform data, amassed since the end of the 1990s, has put these members of the plasminogen activation system into the forefront of prognostic/predictive cancer biomarkers relevant to predict the clinical course of cancer patients and their response to cancer therapy. The present review focuses on the molecular characteristics of the disease forecast biomarkers urokinase-type plasminogen activator and plasminogen activator inhibitor type-1, and techniques to quantitatively assess these cancer biomarkers, in the context of potential clinical application and personalized disease management.",

author = "Karin Mengele and Rudolf Napieralski and Viktor Magdolen and Ute Reuning and Apostolos Gkazepis and Fred Sweep and Nils Brunner and John Foekens and Nadia Harbeck and Manfred Schmitt",

year = "2010",

month = jul,

doi = "10.1586/erm.10.73",

language = "English",

volume = "10",

pages = "947--962",

journal = "Expert Review of Molecular Diagnostics",

issn = "1473-7159",

publisher = "Taylor & Francis",

number = "7",

}

TY - JOUR

T1 - Characteristics of the level-of-evidence-1 disease forecast cancer biomarkers uPA and its inhibitor PAI-1

AU - Mengele , Karin

AU - Napieralski, Rudolf

AU - Magdolen, Viktor

AU - Reuning, Ute

AU - Gkazepis, Apostolos

AU - Sweep, Fred

AU - Brunner, Nils

AU - Foekens, John

AU - Harbeck, Nadia

AU - Schmitt, Manfred

PY - 2010/7

Y1 - 2010/7

N2 - In cancer, the serine protease urokinase-type plasminogen activator, its inhibitor (plasminogen activator inhibitor type-1) and the receptor (CD87), among other proteolytic factors, are involved in tumor cell dissemination and turnover of the extracellular matrix. Unsurprisingly, a battery of very uniform data, amassed since the end of the 1990s, has put these members of the plasminogen activation system into the forefront of prognostic/predictive cancer biomarkers relevant to predict the clinical course of cancer patients and their response to cancer therapy. The present review focuses on the molecular characteristics of the disease forecast biomarkers urokinase-type plasminogen activator and plasminogen activator inhibitor type-1, and techniques to quantitatively assess these cancer biomarkers, in the context of potential clinical application and personalized disease management.

AB - In cancer, the serine protease urokinase-type plasminogen activator, its inhibitor (plasminogen activator inhibitor type-1) and the receptor (CD87), among other proteolytic factors, are involved in tumor cell dissemination and turnover of the extracellular matrix. Unsurprisingly, a battery of very uniform data, amassed since the end of the 1990s, has put these members of the plasminogen activation system into the forefront of prognostic/predictive cancer biomarkers relevant to predict the clinical course of cancer patients and their response to cancer therapy. The present review focuses on the molecular characteristics of the disease forecast biomarkers urokinase-type plasminogen activator and plasminogen activator inhibitor type-1, and techniques to quantitatively assess these cancer biomarkers, in the context of potential clinical application and personalized disease management.

U2 - 10.1586/erm.10.73

DO - 10.1586/erm.10.73

M3 - Journal article

SN - 1473-7159

VL - 10

SP - 947

EP - 962

JO - Expert Review of Molecular Diagnostics

JF - Expert Review of Molecular Diagnostics

IS - 7

ER -

Characteristics of the level-of-evidence-1 disease forecast cancer biomarkers uPA and its inhibitor PAI-1

Abstract

UN SDGs

Access to Document

Fingerprint

Cite this